Topics covered: Urology companies and latest developments, Technology platform companies, Stocks to worry about, Stock recommendations, Safety concerns, Public and private funding, PIPES and structured financing, Outsourcing trends & CRO, Outlook for oncology companies, Late-stage product companies, FDA Approval Process, Failures in oncology trials, Development stage companies, Big Pharma partnerships
